Medical Oncology

AML

Questions discussed in this category

For patients receiving outpatient venetoclax/azacitidine who develop profound neutropenia with ANC <200, do you admit for monitoring during the nadir in the absence of fever?

If not, what instructions do you give to patients regarding checking temperature at home/return precautions?

2 Answers available

Is a patient with secondary myeloid sarcoma a candidate for hematopoietic stem cell transplant?

2 Answers available

How do you factor time from past cytotoxic chemotherapy exposure into diagnosing therapy-related AML?

Many patients have had prior chemotherapy exposure with newly diagnosed AML that may not have classic therapy-related cytogenetics. How do you a...

1 Answer available

Would you consider holding treatment with hypomethylating agents and venetoclax in elderly with AML who achieve CR and are MRD negative?

1 Answer available

Would you use a myeloablative or reduced intensity conditioning regiment for a pediatric or AYA patient who does not recover their counts after treatment for AML, but remains disease free?

Would you test for bone marrow failure syndromes before beginning the conditioning regimen?

1 Answer available

At what level of bone marrow disease would you agree to proceed with transplant for a patient with refractory AML?

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

1 Answer available

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

2 Answers available

What frontline therapy would you offer for a patient who is elderly or unfit for standard induction therapy with both IDH-2 and FLT-3 ITD mutations?

1 Answer available

How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?

Would you consider “bridging” therapy with something like an HMA?

1 Answer available

Would you consider adding Enasidinib to frontline combination therapy with HMA and Venetoclax in a patient with newly diagnosed AML with IDH2 mutation that is >75 or unfit for standard induction therapy?

1 Answer available

What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?

1 Answer available

For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?

Does acute leukemia sub-type affect your decision?

1 Answer available

How do you diagnose acute leukemia-mixed phenotype?

What is your preferred treatment?

1 Answer available

How do you manage persistent cytopenias in patients with AML who achieve a complete remission with incomplete count recovery after venetoclax and HMA?

(i.e. CRi)

2 Answers available

How much later after starting a hypomethylating agent in an elderly patient with AML being treated in the upfront setting can venetoclax be started?

Can it be added after 2 or 3 cycles of HMA?

1 Answer available

Papers discussed in this category

Fertil. Steril., 2013 Sep 05

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.

Cell stem cell, 2017-09-07

Blood,

The World Health Organization (WHO) classification of the myeloid neoplasms.

Blood, 2019-01-03

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Leukemia, 2019 Oct 18

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.

N. Engl. J. Med.,

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Nature medicine, 2015-02

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.

Clin Infect Dis,

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Medical Oncology

AML

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology